One peptide drug class is approved on the strength of exactly that reversal. Leuprolide raises luteinizing hormone and follicle stimulating hormone when you inject it once. Testosterone or estrogen climbs with them. Keep injecting it daily and the same molecule drives those hormones down instead. Its label states both halves of the sequence, and puts testosterone at castrate levels within two to four weeks of starting.1
That is a hormone-raising peptide sold as a hormone blocker. The reversal is the therapy working as designed, not a side effect, a bad batch or a dose error.
How can one molecule do both things?
Receptors are the reason. They read the pattern of a signal, not only its size.
A receptor exposed to a signal without a break stops answering as loudly. It pulls copies off the cell surface, uncouples the ones left behind, or does both. Those two mechanisms are what you will see called downregulation and desensitization. Your own hormones are released in pulses partly because of this. A drug that floods the same receptor continuously does something different from what the pulse did, not a stronger version of it.
Pharmacology has names for the fast and slow versions, tachyphylaxis and tolerance. None of it is peculiar to peptides. Decongestant sprays and nitrates for chest pain behave the same way.
So the first injection and the thirtieth are not asking the same question of the body. Whether that matters for any given compound is a measurement, and the measurement exists for very few of them.
Which peptide drugs are built on the reversal?
The GnRH drugs are the clearest case. An entire therapy is built on it.
Leuprolide is a nine-amino-acid analog of gonadotropin releasing hormone, the signal that tells the pituitary to release LH and FSH. The Lupron label describes an initial increase in both, with a transient rise in gonadal steroids. Continuous daily administration then decreases LH and FSH. Testosterone falls to castrate levels in men and estrogens to postmenopausal levels in premenopausal women, within two to four weeks of starting.1 Those levels have been shown to hold in prostate cancer patients for as long as five years.1 Normal function usually returns four to twelve weeks after the drug is stopped.1
The label also carries the consequence of that first phase as a warning rather than a footnote. Serum testosterone rises initially, and symptoms of prostate cancer can transiently worsen during the first weeks of treatment.1 A compound used for its suppression has a stimulating phase that has to be managed on the way through. Our leuprolide page carries the compound record.
Why does one GnRH drug take four weeks and another one day?
Because only one of them has to desensitize the receptor first.
Degarelix reaches the same endpoint from the other side. Its label describes it as a GnRH receptor antagonist that binds pituitary GnRH receptors reversibly and reduces gonadotropin release, so testosterone falls without the receptor ever being overstimulated.2 Blocking a receptor takes effect as soon as the drug is present. Wearing one out takes weeks of repeated dosing.
The two labels put numbers on that difference. Degarelix reports 52 percent of patients at or below 50 nanograms per deciliter of testosterone by day one, 96 percent by day three, 99 percent by day seven and 100 percent by day 28, with 97.2 percent holding that level from day 28 through day 364.2 Leuprolide's label puts castrate levels at two to four weeks from starting.1
| Leuprolide, an agonist | Degarelix, an antagonist | |
|---|---|---|
| What it does at the receptor | overstimulates it until it stops answering1 | binds it reversibly and blocks it2 |
| First days | LH, FSH and gonadal steroids rise1 | 52 percent at castrate testosterone by day one2 |
| Time to castrate levels | two to four weeks1 | 100 percent by day 282 |
Both drugs reach the same destination at the same receptor. The four-week wait on the agonist is the reversal itself taking time to happen. That is why the two labels report such different first weeks for the same endpoint.
What happened when the growth hormone peptides were dosed repeatedly?
Two of the growth hormone peptides have been through it. The attenuation was partial in both.
Nine healthy young men were given 100 micrograms of GHRP-2 under the skin daily for five days. Growth hormone was sampled on days one, three and five. Mean peak concentrations ran 83, 59 and 51 micrograms per liter across those three days. Growth hormone was still being released on the last day, and the analysis still found the drop significant.3
Adults injecting hexarelin twice daily for sixteen weeks saw the growth hormone response to a test injection fall from an area under the curve of 19.1 to 10.5, then measure 19.4 four weeks after the course ended. The authors report that final figure as not significantly different from where it started.4
A quieter result sits inside both studies. IGF-1 held flat across all six days of the GHRP-2 measurements.3 In the hexarelin study, IGF-1, IGF binding protein-3, total body fat, lean body mass and bone mineral density were all unchanged at week sixteen.4 So what shrank was the hormone spike, and across sixteen weeks that spike moved nothing further down the chain that anyone could measure. Those two studies are also the basis of the cycling advice attached to this family. Our guide to how long peptides take to work handles the timeline question in full.
Has anyone measured this for BPC-157 or TB-500?
No, and the reason sits one layer back from a missing study.
Finding out whether a compound reverses direction takes repeated dosing in people with the same endpoint measured each time. Most of the catalog has no human measurement to repeat. As of November 15, 2026, 133 of the 440 compounds in this library have no qualifying clinical trial on record, 172 have no indexed clinical trial publication, and 54 have no stored records at all.5
BPC-157 shows the shape of it. Its row carries 245 matched papers and 3 registered trials against zero clinical trial publications.5 So for the most popular healing compound on the market, the direction of effect at month three has no answer at all, thin or otherwise. A product page describing what a compound does is describing a first dose at best.
The absence claim here is the weakest thing on this page. We checked this site's own evidence index, built from Europe PMC publications and ClinicalTrials.gov registrations. It states plainly that a missing record does not establish that no study exists.5 A compound can also have real research without an indexed clinical trial, because the counts above come from an indexer's subject headings and not from a person reading each paper.5
How do you tell which case you are in?
The kind of document decides it. The three cases leave different paper trails.
- Deliberate and documented: an approved label states both phases, as the Lupron label does for LH, FSH and the gonadal steroids.1
- Measured and unwanted: a published trial dosed people repeatedly and reported the same endpoint at more than one time point, as the GHRP-2 and hexarelin studies did.34
- Never looked at: the compound has no clinical trial publication, so the only account of what continued use does is a seller's product description.5
The dosage chart names the source type behind every dose figure on this site. The tier tells you which of these three you are reading. A figure drawn from an approved label sits on a document that had to describe both phases. A community practice figure sits on nobody's measurement of the second one.
Common questions
Does this mean peptides stop working?
These are two different questions. Reversal is a compound pushing a measure the other way. A response that simply fades is attenuation. The hexarelin and GHRP-2 studies measured attenuation, and in the hexarelin case it came back after four weeks off.4 Our guide to how long peptides take to work covers the fading question and the cycling advice built on it.
Is a stimulating phase before suppression the same as a side effect?
On the Lupron label they are handled separately. The clinical pharmacology section describes the initial testosterone rise as part of how the drug works. Its clinical consequence appears under warnings: a transient worsening of prostate cancer symptoms in the first weeks.1 One document, two framings, because a mechanism and its effect on a patient are different claims.
Why are some hormones released in pulses at all?
Because a receptor answers a pattern, not just a concentration. Continuous exposure is what triggers the desensitizing response described above, so pulsed release keeps the signal effective. That physiology is what the GnRH drugs exploit by replacing the pulse with a steady presence.
Can I tell from a vial whether this applies?
No, and nothing about the vial carries that information. Direction of effect over weeks belongs to the molecule and the schedule it was studied under, not to the powder in front of you. Our guides to what a peptide half-life is and why most peptides have no human evidence cover the two things a vial cannot tell you.
Related reading
- How Long Do Peptides Take to Work?
- What Is a Peptide Half-Life? Why It Differs From How Long It Works
- Why Most Peptides Have No Human Evidence
- The Growth Hormone Peptides, Sorted Out
- Are Peptides Safe? What Actually Goes Wrong
Sources
- Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. European Journal of Endocrinology 1998;139(4):395-401. https://academic.oup.com/ejendo/article/139/4/395/6748355 read via a reproduction: publisher abstract page opened November 16, 2026, full text paywalled ↩1 ↩2 ↩3
- Rahim A, O'Neill PA, Shalet SM. Growth Hormone Status during Long-Term Hexarelin Therapy. The Journal of Clinical Endocrinology & Metabolism 1998;83(5):1644-1649. https://academic.oup.com/jcem/article/83/5/1644/2865542 read via a reproduction: publisher abstract page opened November 16, 2026, full text paywalled ↩1 ↩2 ↩3 ↩4

